/ obesity drugs
The Weight Loss Market Can Surge to $400 B by 2032, and these Stocks Will Rule it
Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position.
July 12, 2024LLY vs NVO: Which One is Likely to Become a $1T Company First
Tackling growing waistlines is expected to yield much shareholder value.
February 08, 2024